Literature DB >> 22009289

Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids.

S Tobudic1, W Poeppl, C Kratzer, A Vychytil, H Burgmann.   

Abstract

Peritoneal dialysis used in the treatment of patients with end-stage renal failure is often complicated by peritonitis. Staphylococcus aureus peritonitis is severe, particularly if caused by a methicillin-resistant strain (MRSA). Intraperitoneal administration of drugs for treatment of peritonitis is preferable to intravenous or oral routes because of the resulting higher local antibiotic concentrations. However, peritoneal dialysis fluids (PDFs) have a bacteriostatic effect, which may compromise the efficacy of antibiotics. The bactericidal efficacy of vancomycin, teicoplanin, daptomycin and ceftobiprole was studied in the PDFs Dianeal PD4® (glucose 1.36%), Physioneal 40® (glucose 1.36%), Extraneal® (7.5% icodextrin), and Nutrineal PD4® (1.1% amino acid) using time-kill curves. To simulate in vivo conditions, human serum albumin was added at a final concentration of 2 g/l. All four PDFs had a bacteriostatic effect on the growth of the MRSA test isolate. All antibiotics showed less activity in PDFs compared to control broth. Vancomycin and teicoplanin achieved the greatest reduction in bacterial numbers in the amino-acid containing PDF Nutrineal PD4®. Daptomycin showed its highest activity in Extraneal® and better overall efficacy than the other tested antibiotics. Ceftobiprole showed no killing activities in any of the four PDFs. Based on these in vitro data we conclude that the choice of PDFs for intraperitoneal administration is not trivial and could be crucial for therapy outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009289     DOI: 10.1007/s10096-011-1446-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  Peritoneal dialysis-related infections recommendations: 2010 update.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Judith Bernardini; Ana E Figueiredo; Amit Gupta; David W Johnson; Ed J Kuijper; Wai-Choong Lye; William Salzer; Franz Schaefer; Dirk G Struijk
Journal:  Perit Dial Int       Date:  2010 Jul-Aug       Impact factor: 1.756

Review 2.  Peritoneal dialysis-related infections recommendations: 2005 update.

Authors:  Beth Piraino; George R Bailie; Judith Bernardini; Elisabeth Boeschoten; Amit Gupta; Clifford Holmes; Ed J Kuijper; Philip Kam-Tao Li; Wai-Choong Lye; Salim Mujais; David L Paterson; Miguel Perez Fontan; Alfonso Ramos; Franz Schaefer; Linda Uttley
Journal:  Perit Dial Int       Date:  2005 Mar-Apr       Impact factor: 1.756

3.  In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.

Authors:  Frances L Clouse; Laurie B Hovde; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

Review 4.  Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use.

Authors:  Filip de Vin; Peter Rutherford; Dirk Faict
Journal:  Perit Dial Int       Date:  2009 Jan-Feb       Impact factor: 1.756

Review 5.  Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them.

Authors:  William Salzer
Journal:  Perit Dial Int       Date:  2005 Jul-Aug       Impact factor: 1.756

6.  Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis.

Authors:  Miguel Pérez Fontan; Ana Rodríguez-Carmona; Rafael García-Naveiro; Miguel Rosales; Pedro Villaverde; Francisco Valdés
Journal:  Perit Dial Int       Date:  2005 May-Jun       Impact factor: 1.756

7.  The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth.

Authors:  E Tuomanen; R Cozens; W Tosch; O Zak; A Tomasz
Journal:  J Gen Microbiol       Date:  1986-05

Review 8.  Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials.

Authors:  Kathryn J Wiggins; David W Johnson; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Am J Kidney Dis       Date:  2007-12       Impact factor: 8.860

9.  Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; John R Hotchkiss; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 10.  Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

Authors:  Christopher F Carpenter; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2004-03-11       Impact factor: 9.079

View more
  7 in total

1.  The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis.

Authors:  M Kussmann; L Schuster; M Zeitlinger; P Pichler; G Reznicek; M Wiesholzer; H Burgmann; W Poeppl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-04       Impact factor: 3.267

2.  Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.

Authors:  Manuel Kussmann; Linda Schuster; Sarah Wrenger; Petra Pichler; Gottfried Reznicek; Heinz Burgmann; Wolfgang Poeppl; Markus Zeitlinger; Martin Wiesholzer
Journal:  Perit Dial Int       Date:  2016-09-28       Impact factor: 1.756

Review 3.  Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature.

Authors:  James F Gilmore; Miae Kim; Mary T LaSalvia; Monica V Golik Mahoney
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

4.  Successful Treatment of a Pacemaker Infection with Intraperitoneal Daptomycin.

Authors:  Anne B Taegtmeyer; Nina Kononowa; Dominique Fasel; Manuel Haschke; Felix Burkhalter
Journal:  Perit Dial Int       Date:  2016 Jan-Feb       Impact factor: 1.756

5.  Compatibility of fosfomycin with different commercial peritoneal dialysis solutions.

Authors:  M Kussmann; A Baumann; S Hauer; P Pichler; M Zeitlinger; M Wiesholzer; H Burgmann; W Poeppl; G Reznicek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-06       Impact factor: 3.267

Review 6.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

7.  Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa.

Authors:  Manuel Kussmann; Stefan Hauer; Petra Pichler; Gottfried Reznicek; Heinz Burgmann; Wolfgang Poeppl; Markus Zeitlinger; Martin Wiesholzer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-15       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.